BIOTECH (93) – RAPT Therapeutics: Zelnecirnon (RPT193, CCR4 Inhibitor) got Clinical Hold February 20, 2024February 20, 2024
BIOTECH (92) – Vertex Non-Opioid Replacement NaV1.8 Inhibitor Suzetrigine (VX-548) Phase 3 February 20, 2024February 20, 2024
BIOTECH (91) – Replicate Bioscience: Self-Replicating mRNA against Therapy-Acquired Neoantigen February 19, 2024
부러우면 지는거다 (25) – Victor Gonzalez: Chemist with Art Pigments Analysis February 19, 2024February 19, 2024
BIOTECH (90) – Iovance Biotherapeutics: FDA Accelerated Approval of lifileucel (Amtagvi), the first Tumour-Infiltrating Lymphocyte (TIL) Cancer Therapy February 19, 2024
BIOTECH (89) Cymabay Therapeutics: Seladelpar, an oral, selective peroxisome proliferator-activated receptor delta (PPARδ) agonist February 18, 2024February 19, 2024
BIOTECH (87) – Gilead’s Magrolimab (Hu5F9-G4) CD47-SIRPα blocker with Azacitidine for AML Phase 3 ENHANCE Study Terminated & Solid Tumor Partial Clinical Hold February 18, 2024